Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.72 USD
+0.14 (8.86%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $1.71 -0.01 (-0.58%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
Coherus BioSciences, Inc. [CHRS]
Reports for Purchase
Showing records 21 - 40 ( 70 total )
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Things Should Start to Turn; Adjusting PT to $24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Set to Go Back on the Offense; Adjusting PT to $26; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Cimerli Comes to the Scene Just in Time; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
A Second Commercial Product With Others in the Wings; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Challenges for 2022 But the Outlook for 2023 and Beyond Looks Bright; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Toripalimab Receives CRL but Clinical Data Appears Sufficient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Udenyca Continues to Feel Pricing Pressure but New Product Launches Should Help Regain Momentum; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Toripalimab Looks in Good Stead in NPC, FDA Stance Likely Limits Competition
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Doubling Down on Immuno-Oncology by Exercising Anti-TIGIT mAb Option; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Coherus Biosimilars Business Shouldn?t Be Overlooked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Toripalimab Shows Survival Benefit in NSCLC Phase 3 Prompting BLA Discussion Request With the FDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Peg Market Remains Tough But Better Days Lie Ahead; Reiterate Buy, Lower PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Udenyca On-Body Injector Shows Bioequivalence in Human Study with a 2022 US Submission Planned; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
More Promising Toripalimab Data, This Time in 1st Line NSCLC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Udenyca Starts Moving in the Right Direction Again; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Updating Our Model to Include Toripalimab; Reiterate Buy, Raise Price Target to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D